DIRECTOR FINANCIAL PLANNING, US COMMERCIAL

The Director, Financial Planning – US Commercial is a key business partner to the Menarini Stemline Oncology business unit commercial organization in the US region. In this role, the incumbent supports the commercial teams by assisting in financial planning processes, timely reporting of financial metrics, and insightful analysis to gauge business performance and resource allocation that aligns with organizational priorities. Please note: This position is classified as a corporate office position. In accordance with the New York state employer convenience rule, Stemline will withhold New York state income taxes for all corporate office employees, regardless of whether these employees work in New York or remotely.

Responsibilities

• Support financial planning activities such as the annual budget, reforecasts, and strategic plan with special emphasis on commercial functions under the SVP – US Commercial and Market Access
• Quantify financial risks and opportunities for top and bottom line against budget
• Work with US commercial teams to bridge demand forecasts into gross-to-net sales budget and reforecasts
• Report on key metrics for financial performance measurement and forecasting accuracy including but not limited to gross-to-net sales, gross, direct and contribution margin
• Understand SAP and track operational expenses, reporting back to commercial leaders and adjusting accordingly
• Review classification of operating expenses to ensure appropriate allocation to product, expense type, and cost center
• Track and report on fiscal year commitment levels against activities and materials budgets at a product level and provide training/support as needed to ensure team members are accurately tracking expenses in a timely manner
• Ensure that financial planning submissions comply with Menarini financial reporting requirements
• Work with sales operations and commercial leadership to measure field force goal attainment impact versus budgeted incentive compensation
• Reinforce financial timelines, policies, and procedures with assigned functions
• Guide US commercial functions on the use of the Tagetik planning system to achieve expected utilization levels and assure its successful adoption
• Perform ad-hoc analyses and present findings to senior finance and commercial management
• Participate in internal cross-functional teams on financial and operational projects as assigned

Requirements

• Bachelor’s degree in Business, Accounting, or Finance required; MBA preferred
• Seven to ten years in a Financial Planning & Analysis function
• Strong customer focus with dedication to quality and willingness to address business-critical issues outside normal business hours
• Superior communication skills with the ability to adapt to different audiences
• Strong proficiency in MS Excel/PowerPoint or Google Sheets/Slides required
• Familiarity with SAP S/4 and CCH Tagetik is a big plus
• Prior experience supporting a commercial organization in a life sciences industry
• Good understanding of healthcare payor systems and distribution models is a plus
• Prior biopharmaceutical product launch experience will be valued highly
• Strong organizational skills and time management; ability to manage a diverse range of simultaneous projects

Compensation and Benefits

Base Salary Range: $205,000 – $235,000. Menarini Stemline offers generous compensation and benefits packages, including:

• Short- and Long-Term Incentive Programs
• Fidelity 401(k) with company match
• Anthem Premier PPO and HDHP insurance plans
• Company-paid Basic Life & AD&D insurance
• Pre-tax FSA/HSA programs

About Menarini Group

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. With nearly 135 years of history, Menarini is a leading international biopharmaceutical company committed to advancing health through innovation, research, and quality. The Group is present in 70 countries, with products sold in 140 locations worldwide, and employs around 18,000 people across 18 manufacturing sites on six continents. Menarini’s five pillars — high-quality therapeutics and diagnostics, ethics, dedication to innovation, strong people-centricity, and environmental sustainability — underpin its purpose-driven culture.

The acquisition of Stemline Therapeutics in June 2020 strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Key oncology assets include Tagraxofusp (a first-in-class CD123-targeted therapy for blastic plasmacytoid dendritic cell neoplasm), Selinexor (a selective inhibitor of nuclear export for hematologic cancers and solid tumors), and Elacestrant (an oral SERD for hormone receptor-positive advanced breast cancer, FDA-approved in 2023). Menarini also invests in liquid biopsy diagnostics through its affiliate Menarini Silicon Biosystems, whose CELLSEARCH CTC test is the only FDA-cleared blood test for detecting circulating tumor cells in metastatic breast, prostate, and colorectal cancers.